Literature DB >> 18573171

Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells.

Andreas Draube1, Marc Beyer, Jürgen Wolf.   

Abstract

In acute myeloid leukemia (AML) blasts can be differentiated into dendritic cell (DC) like cells (AML-DC). These cells have a mature DC-like phenotype, are strong stimulators in mixed leukocyte reactions and can be used to generate leukemia-specific cytotoxic T cells. However, recent reports about naturally existing leukemic DC with immunoregulatory dysfunctions in peripheral blood of AML patients caused concerns about the use of AML-DC for therapeutic purposes. Systematic intra-individual comparisons between AML-DC and non-leukemic DC derived from monocytes (MoDC) in AML patients are missing. Thus, we investigated the ability to generate MoDC from peripheral blood of 17 AML patients in first remission and their functional integrity to stimulate leukemia-specific T cells by simple coculture with leukemic blasts. Phenotypic analysis of AML-DC and MoDC from the same individual patients revealed that MoDC exhibit a more homogenous mature DC phenotype. Additionally, functional analysis demonstrated the ability of remission MoDC to activate autologous leukemia-specific T cells in 11 of 12 patients, whereas AML-DC led to a specific T cell activation in four of eight patients. The presented findings might have impact on the design of further therapeutic studies using autologous antigen-presenting cells.

Entities:  

Mesh:

Year:  2008        PMID: 18573171     DOI: 10.1111/j.1600-0609.2008.01110.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  9 in total

Review 1.  Immunotherapy prospects for acute myeloid leukaemia.

Authors:  A J Barrett; K Le Blanc
Journal:  Clin Exp Immunol       Date:  2010-05-31       Impact factor: 4.330

Review 2.  Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia.

Authors:  Daniel Christoph Amberger; Helga Maria Schmetzer
Journal:  Transfus Med Hemother       Date:  2020-11-05       Impact factor: 3.747

3.  Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system.

Authors:  C Arndt; A Feldmann; M von Bonin; M Cartellieri; E-M Ewen; S Koristka; I Michalk; S Stamova; N Berndt; A Gocht; M Bornhäuser; G Ehninger; M Schmitz; M Bachmann
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

Review 4.  Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.

Authors:  Hanna A Knaus; Christopher G Kanakry; Leo Luznik; Ivana Gojo
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

Review 5.  Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?

Authors:  Kordelia Barbullushi; Nicolò Rampi; Fabio Serpenti; Mariarita Sciumè; Sonia Fabris; Pasquale De Roberto; Nicola Stefano Fracchiolla
Journal:  Cancers (Basel)       Date:  2022-06-17       Impact factor: 6.575

Review 6.  DC-based immunotherapy for hematological malignancies.

Authors:  Toshio Kitawaki
Journal:  Int J Hematol       Date:  2013-12-31       Impact factor: 2.490

Review 7.  Recent advance in antigen-specific immunotherapy for acute myeloid leukemia.

Authors:  Norimitsu Kadowaki; Toshio Kitawaki
Journal:  Clin Dev Immunol       Date:  2011-10-19

8.  Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission.

Authors:  Barbara Beck; Daniela Dörfel; Felix S Lichtenegger; Christiane Geiger; Lysann Lindner; Martina Merk; Dolores J Schendel; Marion Subklewe
Journal:  J Transl Med       Date:  2011-09-13       Impact factor: 5.531

Review 9.  Can Dendritic Cell Vaccination Prevent Leukemia Relapse?

Authors:  Liam J O'Brien; Camille Guillerey; Kristen J Radford
Journal:  Cancers (Basel)       Date:  2019-06-22       Impact factor: 6.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.